Artelo Biosciences (ARTL) Liabilities and Shareholders Equity (2014 - 2025)

Artelo Biosciences (ARTL) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 40.38% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $14.9 million (down 51.04% YoY), while the FY2025 annual figure was $2.8 million, down 40.38% from the prior year.
• Liabilities and Shareholders Equity fell to $2.8 million in Q4 2025 per ARTL's latest filing, from $4.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $29.0 million in Q4 2021 and bottomed at $2.8 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $13.5 million across 5 years, with a median of $12.8 million in 2021.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 253.22% — and 2025, when it sank 66.05%.
• Artelo Biosciences' Liabilities and Shareholders Equity stood at $29.0 million in 2021, then fell by 29.58% to $20.4 million in 2022, then tumbled by 36.14% to $13.0 million in 2023, then plunged by 63.98% to $4.7 million in 2024, then plunged by 40.38% to $2.8 million in 2025.
• Business Quant data shows ARTL's Liabilities and Shareholders Equity at $2.8 million in Q4 2025, $4.3 million in Q3 2025, and $4.4 million in Q2 2025.